The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis

American Journal of Psychiatry

Volumn 175, Issue 2, 2018, Pages 150-158

  Wilkinson, Samuel T ^a   Ballard, Elizabeth D ^b   Bloch, Michael H ^c   Mathew, Sanjay J ^d   Murrough, James W ^a   Feder, Adriana ^e   Sos, Peter ^f   Wang, Gang ^a   Zarate, Carlos A ^g   Sanacora, Gerard ^g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f CHARLES UNIVERSITY   (Czech Republic)

^g CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MIDAZOLAM; SODIUM CHLORIDE; AMINO ACID RECEPTOR BLOCKING AGENT;

BECK DEPRESSION INVENTORY; COMPARATIVE STUDY; CONFERENCE PAPER; DEPRESSION; DEPRESSION ASSESSMENT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT; SELF REPORT; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SUICIDAL IDEATION; TREATMENT DURATION; ADULT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR DEPRESSION; MALE; META ANALYSIS; MIDDLE AGED; MULTILEVEL ANALYSIS; PSYCHOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; LINEAR MODELS; MALE; MIDDLE AGED; MULTILEVEL ANALYSIS; SELF REPORT; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 85041696970     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17040472     Document Type: Conference Paper

References (35)

1. Aleman A, Denys D: Mental health: a road map for suicide research and prevention. Nature 2014;509:421-423
2. Griffiths JJ, Zarate CA Jr, Rasimas JJ: Existing and novel biological therapeutics in suicide prevention. Am J Prev Med 2014;47(suppl 2):S195-S203
3. Curtin SC, Warner M, Hedegaard H: Increase in suicide in the United States, 1999-2014. NCHS Data Brief 2016; no 241:1-8
4. Cavanagh JT, Carson AJ, Sharpe M, et al: Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003;33:395-405
5. National Action Alliance for Suicide Prevention, Research Prioritization Task Force: A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. Rockville, Md, National Action Alliance for Suicide Prevention, 2014
6. Cipriani A, Hawton K, Stockton S, et al: Lithium in the prevention of suicide in mood disorders: updated systematic review and metaanalysis. BMJ 2013;346:f3646
7. Mann JJ: The medical management of depression. N Engl J Med 2005;353:1819-1834
8. Brown GK, Ten Have T, Henriques GR, et al: Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA 2005;294:563-570
9. Linehan MM, Comtois KA, Murray AM, et al: Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006;63:757-766
10. Berman RM, Cappiello A, Anand A, et al: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354
11. Zarate CA Jr, Singh JB, Carlson PJ, et al: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864
12. Zarate CA Jr, Brutsche NE, Ibrahim L, et al: Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71:939-946
13. Diazgranados N, Ibrahim L, Brutsche NE, et al: Arandomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802
14. Murrough JW, Iosifescu DV, Chang LC, et al: Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170:1134-1142
15. Ballard ED, Ionescu DF, Vande Voort JL, et al: Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res 2014;58:161-166
16. Diaz Granados N, Ibrahim LA, Brutsche NE, et al: Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605-1611
17. Murrough JW, Soleimani L, De Wilde KE, et al: Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 2015;45:3571-3580
18. Price RB, Iosifescu DV, Murrough JW, et al: Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014;31:335-343
19. Burke DL, Ensor J, Riley RD: Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017;36:855-875
20. Feder A, Parides MK, Murrough JW, et al: Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:681-688
21. Hu YD, Xiang YT, Fang JX, et al: Single iv ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 2015;46:623-635
22. Sos P, Klirova M, Novak T, et al: Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Lett 2013;34:287-293
23. Valentine GW, Mason GF, Gomez R, et al: The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1) H]-MRS. Psychiatry Res 2011;191:122-127
24. Rodriguez CI, Kegeles LS, Levinson A, et al: Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof of concept. Neuropsychopharmacology 2013;38:2475-2483
25. Kellner CH, Fink M, Knapp R, et al: Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry 2005;162:977-982
26. Wilkinson ST, Sanacora G: Ketamine: a potential rapid-acting antisuicidal agent? Depress Anxiety 2016;33:711-717
27. Mahableshwarkar AR, Zajecka J, Jacobson W, et al: A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function inmajor depressive disorder. Neuropsychopharmacology 2015;40:2025-2037
28. McIntyre RS, Lophaven S, Olsen CK: A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-1567
29. McIntyre RS, Xiao HX, Syeda K, et al: Theprevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs 2015;29:577-589
30. Schak KM, Vande Voort JL, Johnson EK, et al: Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 2016;173:215-218
31. Morgan CJ, Muetzelfeldt L, Curran HV: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121-133
32. Ionescu DF, Swee MB, Pavone KJ, et al: Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 2016;77:e719-e725
33. Vande Voort JL, Morgan RJ, Kung S, et al: Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord 2016;206:300-304
34. Wilkinson ST, Wright D, Fasula MK, et al: Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom 2017;86:162-167
35. Sanacora G, Frye MA, McDonald W, et al: A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017;74:399-405